Amathus Therapeutics, Inc.

Funding reportedLast round: Series A

ResearchCambridge, United States

About Amathus Therapeutics, Inc.

is a biopharmaceutical company based in Cambridge, MA, that specializes in developing small-molecule therapeutics for genetically defined diseases, particularly neurodegenerative and renal disorders. Founded in 2016, the company focuses on creating innovative treatments for conditions such as Parkinson's Disease and Polycystic Kidney Disease. The company is recognized for its expertise in small molecule modulators of organelle-specific chaperones. Its proprietary technology platform allows for precise modulation of mitochondrial and endoplasmic reticulum chaperones, targeting cellular stress response pathways to restore essential cellular functions affected by disease. Amathus has formed a strategic partnership with Merck to advance its pipeline of mitochondrial-targeted candidates, with potential milestone payments exceeding $500 million per program.

What company datasets say Amathus Therapeutics, Inc. raised

Funding, as reported

Reported in all$16Min dollars

Last roundSeries A

Last round size$16M

Last round dateMar 2019

The company, in detail

What they build

Known for

digital solutionsstrategic consultingmanagement consultingcustom software solutionsuser experienceinformation technology and servicesperformance marketingbusiness growthmobile-friendly designproject managementbiotechnology researchdigital marketingdigital transformationmarketing & advertisinginformation technology & servicesperformance-driven strategies

Built with from their website

IoTRemoteCanalMicro

Sector: Research
Industry code: NAICS 54151, SIC 8742
Region: Massachusetts

Research in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Amathus Therapeutics, Inc. in front of investors. Or tell us what we have wrong.

List your startup Send a correction